HIV/AIDS Research
Treatment switch improves results in virologically suppressed patients
Published in Hepatitis Weekly, December 12th, 2005
Gilead Sciences, Inc. (GILD) announced preliminary 24-week data which suggest that HIV-infected treatment-experienced patients who switched from twice-daily Combivir (lamivudine 150 mg/zidovudine 300 mg) to once-daily Truvada (emtricitabine and tenofovir disoproxil fumarate), both in combination with efavirenz, have a higher percentage of virologic suppression below 50 copies/mL at week 24 than baseline. Hemoglobin levels also increased significantly from baseline.
Data from the Combination of Efavirenz and Truvada (COMET) study at the 10th European AIDS Conference (EACS) in Dublin, Ireland was presented by study investigator Peter Ruane, MD of Lifesource Medical Inc....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-12-12)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
Extracorporal liver support shows promise in hepatitis B-associated hepatic failure - Hepatitis D Virus
Hepatitis delta virus RNA genome evolution occurs during long-term replication - Hepatitis Therapy
Glucocerebroside treatment ameliorates ConA hepatitis - Hepatitis Vaccine
Anti-phospholipid antibodies are produced using recombinant hepatitis B vaccine - Hepatitis Vaccine
Insert position, C terminus, and epitope sequence are relevant in vaccine design - Cancer Prevention
Reports add new data to cancer prevention research - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
